查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2015231

全球醫藥契約製造市場：2026-2032年市場預測（依服務類型、分子類型、劑型、治療領域、合約類型、生產規模及製程分類）

Pharmaceutical Contract Manufacturing Market by Service Type, Molecule Type, Dosage Form, Therapeutic Area, Contract Type, Production Scale, Process Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年，醫藥契約製造市場價值1,522.7億美元，預計到2026年將成長至1,647.1億美元，複合年成長率為10.06%，到2032年將達到2978.8億美元。

主要市場統計數據
基準年 2025 1522.7億美元
預計年份：2026年 1647.1億美元
預測年份 2032 2978.8億美元
複合年成長率 (%) 10.06%

權威說明指出，契約製造已從單純的成本削減措施轉變為支持醫藥創新和供應鏈韌性的策略職能。

醫藥契約製造產業在全球醫藥供應鏈中扮演著至關重要的角色，它使創新公司、學名藥生產商和生物相似藥開發商能夠將突破性的實驗室成果轉化為可擴展且符合監管規定的商業產品。外包生產、製劑開發、分析測試和包裝已不再只是降低成本的手段，而是發展成為一種戰略能力，有助於加快產品上市速度、提高產品組合的柔軟性並分散風險。如今，整個價值鏈上的相關人員不再僅僅將契約製造視為產能供應商，而是將其視為共同承擔技術風險管理、合規性和生命週期管理責任的合作夥伴。

技術進步、更嚴格的監管和地緣政治壓力如何共同作用，重新定義契約製造能力和策略採購模式。

近年來，在技術進步、監管日益複雜以及相關人員期望不斷變化的推動下，支持藥物研發和商業化的契約製造模式正在迅速重塑。先進生物製藥和細胞/基因療法的興起迫使合約生產機構（CDMO）投資於無菌注射和低溫運輸平台。同時，連續生產和製程整合正在改變生產經濟效益和設施設計框架。這些變化並非孤立存在，而是同時重塑整個產業的商業性採購模式、資本規劃和人才需求。

了解將於 2025 年實施的美國新關稅對營運和商業的廣泛影響，以及這些關稅將如何重組採購、投資和合約策略。

美國2025年實施的關稅政策調整，為藥品原料、包裝材料和資本設備的採購計算增加了新的複雜性，迫使契約製造生產商及其委託客戶重新審視成本結構和供應風險模型。某些進口材料和設備的關稅提高，導致無菌填充所需組件、專用包裝材料和先進分析儀器的到貨成本上升。這一趨勢正在影響從研發到商業化的整個流程。臨床供應預算受到擠壓，新設施和設備的資本投資計劃被迫修訂，委託方和合約研發生產機構（CDMO）之間的價格談判必須反映原料成本波動加劇的情況。

策略性細分分析揭示了服務、分子、劑型、客戶類型、治療領域、合約模式、生產規模和製程選擇方面的能力需求。

精細的細分分析揭示了服務類型、分子類別、劑型、客戶類型、治療領域、合約模式、生產階段和製程設計方案等方面的能力差距和策略重點的交匯點。服務專長涵蓋分析服務（包括生物分析、法律架構制定和穩定性測試）；研發服務（包括製劑和製程開發）；灌裝服務（包括注射器、單劑量製劑和管瓶灌裝）；生產服務（包括口服液體製劑、口服固態製劑、無菌注射劑和外用製劑）；以及一級包裝和標籤服務（滿足一級包裝需求）。每個服務領域所需的資本投入、監管路徑和技術專長各不相同。能夠無縫協調研發、分析表徵和商業化生產各個階段的公司，能夠為委託公司帶來縮短產品上市時間的實際效益。

美洲、歐洲、中東和非洲以及亞太地區的區域生產能力、監管複雜性和戰略獎勵如何影響製造地地點和採購決策？

區域趨勢決定了產能的佈局、供應風險管理方式以及影響商業性決策的監管節點。在美洲，對無菌注射劑、先進的生物製藥灌裝和包裝以及安全供應鏈的需求正在推動對國內產能和專業領域的投資。該地區監管清晰、市場龐大，且接近性主要贊助商公司的總部，因此對尋求更短前置作業時間和更快技術合作的近岸外包企業和贊助商公司都極具吸引力。

深入了解能力整合、平台專業化和深度客戶夥伴關係如何重塑契約製造供應商的競爭地位。

領先的契約製造和服務供應商之間的競爭格局呈現出能力整合、平台差異化以及超越單純交易關係的更深層客戶夥伴關係的特徵。許多公司正透過提供從研發到商業化的一體化解決方案，向價值鏈上游移動，從而減少技術轉移的阻力並加快商業化進程。這一趨勢體現在以下方面：分析平台的擴展以支持複雜的生物製藥；對無菌灌裝和包裝能力的投資；以及採用數位化品管和生產執行系統以實現更可預測的結果。

為製造商和贊助商提供切實可行的策略行動，以提高柔軟性、降低供應風險，並使商業性框架適應不斷變化的生產實際情況。

產業領導企業應優先採取一系列戰術性和策略措施，將當前的市場動態轉化為永續的競爭優勢。首先，應有選擇地投資於模組化和靈活的生產平台，這些平台能夠處理多種劑型和分子種類，從而實現專案間的快速部署，並減少因設備更換而造成的時間損失。整合強大的分析技術和數位化製程控制將有助於實現品質源自於設計 (QbD) 的理念，並促進從臨床到商業化生產的平穩過渡。

透過與關鍵相關人員的訪談、文件檢驗和基於情境的壓力測試，採用嚴謹的混合研究途徑，獲得了可靠的策略見解。

本分析的研究結合了對行業相關人員的結構化一手訪談、對二手資訊的嚴格整合以及基於情景的供應鏈壓力測試，以確保得出切實可行且令人信服的見解。一手訪談對象包括來自不同贊助公司和契約製造組織 (CMO) 的研發科學、品質保證、法規事務、採購和營運部門的高階領導。這些對話重點在於能力差距、近期投資、技術轉移經驗以及應對政策和供應鏈中斷的實際措施。

簡要概述能力整合、供應多元化和現代合約形式如何塑造契約製造中相互競爭的韌性支柱。

受技術、監管、商業性和地緣政治因素的影響，製藥生產的合約和營運框架正在快速變化。投資於平台多功能性、高級分析和數位化控制的契約製造製造商將更有能力滿足生技藥品和小分子藥物申辦方的複雜需求。策略採購選擇，包括近岸外包和供應商多元化，是管理成本和業務永續營運風險的關鍵工具，尤其是在貿易政策變化可能對投入成本產生重大影響的環境下。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：藥品契約製造市場：依服務類型分類

  • 分析服務
    • 生物分析服務
    • 方法開發
    • 穩定性測試
  • 發展服務
    • 配方開發
    • 製程開發
  • 填充服務
    • 注射器填充
    • 單劑量補充裝
    • 管瓶填充
  • 製造服務
    • 液體
    • 固態口服藥物
    • 無菌注射劑
    • 外用製劑
  • 包裝和標籤
    • 初級包裝
    • 二級包裝

第9章：藥品契約製造市場：依分子類型分類

  • 生物製藥
  • 小分子藥物

第10章：藥品契約製造市場：依劑型分類

  • 液體
    • 口服液
    • 懸浮液
  • 固態劑型
    • 膠囊
    • 藥片
  • 無菌注射劑
  • 外用製劑
    • 乳膏和軟膏
    • 凝膠

第11章：藥品契約製造市場：依治療領域分類

  • 循環系統
  • 中樞神經系統
  • 感染疾病
  • 腫瘤學

第12章：藥品契約製造市場：依合約類型分類

  • 獨家的
  • 非獨家

第13章：醫藥契約製造市場：依生產規模分類

  • 臨床試驗
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業的

第14章：藥品契約製造市場：依工藝分類

  • 批次
  • 連續型

第15章：醫藥契約製造市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：藥品契約製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 藥品契約製造市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國：藥品契約製造市場

第19章 中國：醫藥契約製造市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Cambrex Corporation
  • Catalent, Inc.
  • Fujifilm Diosynth Biotechnologies US, LLC
  • Lonza Group AG
  • PCI Pharma Services, Inc.
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-030EE48515DD

The Pharmaceutical Contract Manufacturing Market was valued at USD 152.27 billion in 2025 and is projected to grow to USD 164.71 billion in 2026, with a CAGR of 10.06%, reaching USD 297.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 152.27 billion
Estimated Year [2026] USD 164.71 billion
Forecast Year [2032] USD 297.88 billion
CAGR (%) 10.06%

An authoritative orientation to how contract manufacturing has transformed from a cost-driven option into a strategic capability for pharmaceutical innovation and supply resilience

The pharmaceutical contract manufacturing arena occupies a pivotal role in the global medicines supply chain, enabling innovators, generics players, and biosimilar developers to translate laboratory breakthroughs into scalable, regulated commercial products. Outsourcing of production, formulation development, analytical testing, and packaging has evolved from a cost containment tactic into a strategic capability that supports speed to market, portfolio flexibility, and risk diversification. Stakeholders across the value chain now view contract manufacturing organizations as partners that co-own technical risk, compliance pathways, and lifecycle management responsibilities rather than as mere capacity vendors.

Today's landscape is shaped by converging pressures: complex biologic modalities that require specialized sterile and cold-chain capabilities; regulatory expectations for robust quality systems and supply traceability; and commercial demands for faster clinical-to-commercial transitions. These dynamics have elevated the importance of integrated service models that combine development expertise, analytical depth, and commercial-scale manufacturing. Consequently, forward-looking sponsors prioritize long-term technical relationships, modular manufacturing footprints, and transparency in supply risk, positioning contract manufacturers as central nodes in pharmaceutical innovation and distribution strategies.

How technological advances, regulatory tightening, and geopolitical pressures are converging to redefine contract manufacturing capabilities and strategic sourcing models

Recent years have seen a rapid reshaping of how contract manufacturing supports drug development and commercialization, driven by technological advances, regulatory complexity, and evolving stakeholder expectations. The rise of advanced biologics and cell and gene therapies has pushed CDMOs to invest in sterile injectables and cold chain platforms, while continuous manufacturing and process intensification have begun to reframe production economics and facility design. These shifts are not isolated; they simultaneously reshape commercial sourcing models, capital planning, and talent requirements across the industry.

Regulators globally are reinforcing expectations for quality-by-design, process robustness, and supply chain transparency, prompting manufacturers and their partners to embed analytics and digital thread capabilities across development and production lifecycles. Meanwhile, the industry's geographic footprint is adapting to geopolitical and trade developments, with localized capacity, dual-sourcing strategies, and nearshoring gaining prominence as mechanisms to mitigate disruption. Taken together, these transformative currents favor contract manufacturers that can demonstrate platform standardization, cross-modal expertise, and an agile approach to integrating regulatory, technical, and commercial needs into cohesive delivery models.

Understanding the broad operational and commercial consequences of new United States tariff measures in 2025 and how they reshape sourcing, investment, and contractual strategies

The tariff policy adjustments implemented by the United States in 2025 have introduced a new layer of complexity into the sourcing calculus for pharmaceutical ingredients, packaging components, and capital equipment, compelling both contract manufacturers and their sponsor customers to revisit cost structures and supply risk models. Increased duties on certain imported materials and equipment have translated into higher landed costs for components essential to sterile filling, specialized packaging substrates, and sophisticated analytical instrumentation. This dynamic has consequences across the development-to-commercial continuum: clinical supply budgets are pressured, capital expenditure plans for new facilities or equipment require recalibration, and pricing discussions between sponsors and CDMOs must account for elevated input cost volatility.

Beyond the direct cost impact, the tariffs have accelerated strategic behaviors that alter long-term industry structure. Some sponsors have prioritized re-shoring or near-shoring initiatives to reduce exposure to trade friction, which in turn increases demand for domestic capacity in steriles, biologics fill-finish, and specialized packaging. Contract manufacturers with flexible production models and multi-jurisdictional footprints have found increased interest from customers seeking rapid contingency options and shorter logistics chains. At the same time, suppliers of raw materials located in tariff-affected geographies are exploring re-certification pathways, dual-sourcing arrangements, and tariff-engineering solutions to preserve competitiveness.

The cumulative effect of these policy changes extends to supplier negotiations and commercial contracting. Cost escalation clauses, pass-through mechanisms, and inventory financing arrangements have become focal points of new contracts. Sponsors and CDMOs are seeking greater transparency on bill-of-materials composition and origin, and are more frequently agreeing to longer-term procurement commitments to secure stable pricing. Moreover, regulatory authorities and industry groups have engaged in dialogue about maintaining supply continuity for essential medicines, which has encouraged stakeholders to develop contingency playbooks that combine strategic stockpiles, multiple manufacturing sites, and prioritized allocation frameworks for critical components.

In sum, tariffs enacted in 2025 function less as a temporary price shock and more as a catalyst for structural change: they have shifted sourcing strategies toward resilience and localization, elevated the value of manufacturing flexibility, and forced sharper alignment between commercial terms and supply chain realities. Organizations that proactively integrate tariff risk into scenario planning, capital investment decisions, and supplier governance will be better positioned to sustain supply continuity and preserve margins while maintaining compliance and product quality.

Strategic segmentation analysis revealing capability demands across services, molecules, dosage forms, customer archetypes, therapeutic focuses, contract models, production scales, and process choices

A nuanced segmentation view reveals where capability gaps and strategic priorities converge across service modalities, molecule classes, dosage formats, customer archetypes, therapeutic focus, contract models, production phases, and process design choices. Service-type specialization spans analytical services that cover bioanalytical work, method development, and stability studies; development services that encompass formulation and process development; filling services that include syringe, unit dose, and vial filling; manufacturing services oriented to liquid orals, solid oral dosage, sterile injectables, and topical formulations; and packaging and labeling services that address primary and secondary packaging needs. Each service strand demands distinct capital intensity, regulatory pathways, and technical competencies, and firms that can offer integrated handoffs between development, analytical characterization, and commercial manufacturing create tangible time-to-market advantages for sponsors.

Molecule type drives technical complexity and facility requirements. Biologics require specialized upstream and downstream processing, cold chain considerations, and sterile handling regimes, while small molecules often align with established solid oral or liquid oral manufacturing platforms. Dosage form segmentation further refines capability needs: liquid dosage formats including oral solutions and suspensions necessitate excipient sourcing and stability expertise; solid dosage capsules and tablets demand robust formulation development and compression/fill capabilities; sterile injectables impose stringent aseptic practices and validated fill-finish suites; and topical dosage forms such as creams, ointments, and gels require formulation rheology control and container compatibility testing.

Customer type and therapeutic area shape commercial engagement models. Biosimilar manufacturers often seek high-volume commercial capacity and regulatory comparability expertise, generic manufacturers prioritize rapid scale-up and cost-efficient tooling, and innovator manufacturers demand integrated development pathways and controlled tech transfer. Therapeutic focus areas, such as cardiovascular, central nervous system, infectious diseases, and oncology, impose differing requirements for clinical supply chain timing, packaging and labeling complexity, and regulatory interaction intensity. Contract type and production scale introduce governance and utilization dynamics: dedicated contracts provide capacity assurance and long-term alignment, whereas non-dedicated models offer flexibility but require more complex scheduling. Clinical-scale production, with phase-specific needs across Phase I, II, and III, requires nimble tech transfer and batch documentation practices that differ materially from commercial-scale operations. Finally, process type-batch versus continuous-affects capital deployment, process monitoring complexity, and implications for scale-up. Continuous processes can enable higher throughput and more consistent product quality for certain modalities but require a higher level of process control and real-time analytical capabilities. Mapping capabilities against these segmentation axes allows stakeholders to identify where to consolidate partnerships, where to invest in capability development, and where to prioritize risk mitigation to support therapeutic and commercial objectives.

How regional capacity, regulatory complexity, and strategic incentives in the Americas, Europe Middle East & Africa, and Asia-Pacific shape manufacturing footprints and sourcing decisions

Regional dynamics are shaping where capacity is built, how supply risk is managed, and which regulatory touchpoints dominate commercial considerations. In the Americas, demand for sterile injectables, advanced biologics fill-finish, and secure supply chains has driven investments in domestic capacity and specialization. This region's combination of regulatory clarity, large commercial markets, and proximity to major sponsor headquarters makes it attractive for nearshoring initiatives and for sponsors seeking shorter lead times and more responsive technical collaboration.

Europe, Middle East & Africa represents a diverse regulatory and capability landscape where established CDMOs co-exist with niche innovators. European manufacturing networks often emphasize harmonized regulatory pathways and advanced process technologies, while countries across the broader region offer differentiated cost structures and emerging specialized capabilities. Cross-border regulatory alignment within this region influences where multicountry batch release strategies and centralized quality oversight are implemented, which affects the design of multi-site manufacturing networks.

Asia-Pacific continues to be a critical capacity hub, offering broad manufacturing bases for small molecules, generics, and an expanding footprint for biologics and sterile manufacturing. The region's competitive cost profile, deep supplier networks for excipients and packaging materials, and growing technical talent pool make it a central node for both clinical and commercial production. Simultaneously, increasing regulatory sophistication in several Asia-Pacific markets and rising domestic demand are pushing local providers to upgrade quality systems and to pursue international certifications, which in turn broadens the set of viable sourcing options for global sponsors.

Across these geographies, supply chain resilience, regulatory convergence efforts, and strategic incentives for local manufacturing are the common themes influencing investment decisions. Sponsors and contract manufacturers must evaluate trade-offs between cost, lead time, regulatory complexity, and risk exposure when configuring global footprints; the optimal approach increasingly blends regional centers of excellence with redundant capacity and rapid-response capabilities.

Insights into how capability consolidation, platform specialization, and deep client partnerships are reshaping competitive positioning among contract manufacturing providers

Competitive dynamics among leading contract manufacturers and service providers are characterized by capability consolidation, platform differentiation, and deeper client partnerships that extend beyond transactional engagements. Many firms are moving up the value chain by offering integrated development-to-commercial solutions that reduce tech transfer friction and accelerate commercialization timelines. This trend is visible in the expansion of analytical platforms that support complex biologics, investments in sterile fill-finish capacity, and the adoption of digital quality and manufacturing execution systems to enable more predictable outcomes.

Strategic partnerships, mergers, and targeted greenfield investments are being used to expand modality coverage and geographic presence, while mid-sized specialized players often succeed by focusing on niche capabilities such as high-potency handling, complex packaging, or rapid-turn clinical supply. For sponsors, the choice of partner reflects a balance between scale, technical specialization, and the depth of regulatory experience. Increasingly, procurement teams value partners who can demonstrate demonstrable process ruggedness, a track record of successful tech transfers, and transparent governance over multi-supplier supply chains.

Talent and leadership continuity are notable differentiators. Organizations that retain cross-functional teams covering development sciences, regulatory affairs, quality assurance, and operational excellence are better equipped to navigate complex projects and minimize time-to-release delays. Additionally, firms that provide clear roadmaps for capacity expansion and contingency management tend to attract longer-term commitments from customers seeking to de-risk their product launches and lifecycle supply.

Practical strategic actions for manufacturers and sponsors to enhance flexibility, mitigate supply risks, and align commercial frameworks with evolving production realities

Industry leaders should prioritize a series of tactical and strategic actions to convert current market dynamics into sustainable advantage. First, invest selectively in modular and flexible manufacturing platforms that can accommodate multiple dosage forms and molecule classes, thereby enabling rapid redeployment across projects and reducing time lost to retooling. Embedding robust analytical technologies and digital process controls will support quality-by-design approaches and facilitate smoother scale-up pathways from clinical to commercial production.

Second, re-evaluate supplier and sourcing strategies to mitigate tariff exposure and logistical risk. This includes diversifying input suppliers, negotiating clearer pass-through clauses, and developing nearshore alternatives where feasible. Transparent supply-of-origin documentation and a proactive approach to supplier qualification will improve negotiating leverage and reduce downstream surprises.

Third, strengthen integrated development pathways by co-locating or tightly coordinating formulation, analytical, and process development teams with manufacturing operations. This alignment shortens feedback loops, accelerates tech transfer, and reduces regulatory friction at the point of scale-up. Complementary to this, establish formal contingency playbooks for critical material shortages and regulatory delays, including prioritized allocation criteria and pre-agreed surge capacity arrangements with trusted partners.

Fourth, adopt outcome-oriented commercial models with customers, such as milestone-linked pricing and risk-sharing arrangements, to better align incentives and accommodate input cost volatility. Develop contract frameworks that include clear escalation mechanisms for input cost shocks while preserving collaborative governance for change management. Finally, prioritize talent development programs that cross-train scientists, quality professionals, and operations staff to build institutional resilience and reduce dependency on single individuals or teams during critical transfer phases.

A rigorous mixed-methods research approach combining primary stakeholder interviews, documentary validation, and scenario stress testing to produce resilient strategic insights

The research underpinning this analysis combined structured primary engagement with industry stakeholders, rigorous secondary source synthesis, and scenario-based supply chain stress testing to ensure actionable and defensible insights. Primary engagement included interviews with senior leaders across development sciences, quality assurance, regulatory affairs, procurement, and operations from a spectrum of sponsor and contract manufacturing organizations. These conversations focused on capability gaps, recent investments, tech transfer experiences, and practical responses to policy or supply disruptions.

Secondary research reviewed regulatory guidance documents, technical white papers, and publicly available corporate disclosures to validate observed trends and to map capability footprints. Where possible, cross-referencing of production platform descriptions, facility audits, and filing histories was used to corroborate claims about service offerings and modality coverage. Scenario-based analysis simulated supply interruptions, tariff-induced cost shocks, and capacity loss events to evaluate the resilience of different sourcing configurations and contract structures.

Analytical methods included capability mapping across the segmentation dimensions, qualitative comparative analysis to identify differentiating practices among high-performing providers, and sensitivity testing of procurement and contracting levers under varying disruption scenarios. The research process emphasized triangulation, seeking concurrence across interview data, documentary evidence, and scenario outcomes to build robust conclusions while acknowledging uncertainty in policy trajectories and capital deployment timelines.

A concise synthesis of how capability integration, supply diversification, and modern contracting form the pillars of competitive resilience in contract manufacturing

The contractual and operational contours of pharmaceutical manufacturing are evolving rapidly under the influence of technological, regulatory, commercial, and geopolitical forces. Contract manufacturers that invest in platform versatility, advanced analytics, and digital controls will be best positioned to serve the complex needs of biologic and small-molecule sponsors alike. Strategic sourcing choices, inclusive of nearshoring and supplier diversification, have become critical levers to manage both cost and continuity risk, particularly in an environment where trade policy shifts can materially affect input economics.

Longer-term competitive advantage will accrue to organizations that can integrate development, analytical, and commercial manufacturing functions to minimize tech transfer friction and compress timelines. At the same time, strong governance over supplier origin and contractual mechanisms that transparently allocate input cost risk will be essential for preserving margins and maintaining reliable supply. The future will favor collaborative, partnership-oriented models that align incentives and create shared accountability for product quality and timely market access. Decision-makers who act decisively to fortify flexible capacity, codify contingency plans, and modernize contracting approaches will convert current disruption into durable strategic benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmaceutical Contract Manufacturing Market, by Service Type

  • 8.1. Analytical Services
    • 8.1.1. Bioanalytical Services
    • 8.1.2. Method Development
    • 8.1.3. Stability Studies
  • 8.2. Development Services
    • 8.2.1. Formulation Development
    • 8.2.2. Process Development
  • 8.3. Filling Services
    • 8.3.1. Syringe Filling
    • 8.3.2. Unit Dose Filling
    • 8.3.3. Vial Filling
  • 8.4. Manufacturing Services
    • 8.4.1. Liquid Orals
    • 8.4.2. Solid Oral Dosage
    • 8.4.3. Sterile Injectables
    • 8.4.4. Topical Formulations
  • 8.5. Packaging & Labeling
    • 8.5.1. Primary Packaging
    • 8.5.2. Secondary Packaging

9. Pharmaceutical Contract Manufacturing Market, by Molecule Type

  • 9.1. Biologics
  • 9.2. Small Molecule

10. Pharmaceutical Contract Manufacturing Market, by Dosage Form

  • 10.1. Liquid Dosage
    • 10.1.1. Oral Solutions
    • 10.1.2. Suspensions
  • 10.2. Solid Dosage
    • 10.2.1. Capsules
    • 10.2.2. Tablets
  • 10.3. Sterile Injectables
  • 10.4. Topical Dosage
    • 10.4.1. Creams & Ointments
    • 10.4.2. Gels

11. Pharmaceutical Contract Manufacturing Market, by Therapeutic Area

  • 11.1. Cardiovascular
  • 11.2. CNS
  • 11.3. Infectious Diseases
  • 11.4. Oncology

12. Pharmaceutical Contract Manufacturing Market, by Contract Type

  • 12.1. Dedicated
  • 12.2. Non Dedicated

13. Pharmaceutical Contract Manufacturing Market, by Production Scale

  • 13.1. Clinical Trial
    • 13.1.1. Phase I
    • 13.1.2. Phase II
    • 13.1.3. Phase III
  • 13.2. Commercial

14. Pharmaceutical Contract Manufacturing Market, by Process Type

  • 14.1. Batch
  • 14.2. Continuous

15. Pharmaceutical Contract Manufacturing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Pharmaceutical Contract Manufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Pharmaceutical Contract Manufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Pharmaceutical Contract Manufacturing Market

19. China Pharmaceutical Contract Manufacturing Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Cambrex Corporation
  • 20.6. Catalent, Inc.
  • 20.7. Fujifilm Diosynth Biotechnologies US, LLC
  • 20.8. Lonza Group AG
  • 20.9. PCI Pharma Services, Inc.
  • 20.10. Recipharm AB
  • 20.11. Samsung Biologics Co., Ltd.
  • 20.12. Siegfried Holding AG
  • 20.13. Thermo Fisher Scientific Inc.
  • 20.14. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTINUOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTINUOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTINUOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)

TABLE 27